
Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

7

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name					
Akin, Gump, Strauss, Hauer & Feld, L.L.P.					
2. Address					
1333 New Hampshire Avenue, NW					
3. Principal Place of Business (if different from line 2)					
City: Washington State/Zip (or Co	ountry) DC 20036				
4. Contact Name Telephone	E-mail (optional) 5. Senate ID				
Donald R. Pongrace 202-887-4000	682-8				
7. Client Name Self	6. House ID				
Pfizer, Inc.	31784				
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report □ ⇒ Termination Date 11. No Lobby INCOME OR EXPENSES – Complete Either Line 12 OR Line 13					
12. Lobbying Firms	13. Organizations				
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this rewere:				
Less than \$10,000	Less than \$10,000				
\$10,000 or more \(\sum \) \(\Rightarrow \) \(\frac{200,000}{\text{lncome (nearest \$20,000)}} \)	\$10,000 or more				
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description				
	☐ Method A. Reporting amounts using LDA defi				
activities on behalf of the client).	☐ Method A. Reporting amounts using LDA defi ☐ Method B. Reporting amounts under section 6 Internal Revenue Code				

Signature		 	
Printed Name and Title	Donald R. Pongrace, Partner		
LD-2 (REV. 6/98)			

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L	.L.P. Client Name Pfizer, Inc.
LOBBYING ACTIVITY. Select as many codes as engaged in lobbying on behalf of the client during the information as requested. Attach additional page(s)	s necessary to reflect the general issue areas in which the ne reporting period. Using a separate page for each coas needed.
15. General issue area code TRA (one per pa	ge)
16. Specific lobbying issues Potential legislation or regulation regarding use	e of certain antihistamines by operators of commercial v
17. House(s) of Congress and Federal Agencies con U.S. House of Representatives U.S. Senate U.S. Department of Transportation	ntacted
18. Name of each individual who acted as a lobbyis	st in this issue area Covered Official Position (if applicable)
Stacy Carlson Henry A. Terhune	
Anthony Foti	
Charles W. Johnson, IV	
J. Robert Joyce	
Susan H. Lent	
Bill Paxon	
Donald R. Pongrace	
Paul G. Scolese	
19. Interest of each foreign entity in the specific issues li	isted on line 16 above 🛛 Check if None
Signature	Date February 14, 2

Form LD-2 (Rev. 6/98) Pag

Registrant Name Akin, Gump	, Strauss, Hauer & Feld, L.L.P	Client Name	Pfizer, Inc.	
LOBBYING ACTIVITY. engaged in lobbying on beha information as requested. A	alf of the client during the re	eporting period.	t the genera Using a se	al issue areas in which the eparate page for each co
15. General issue area code	HCR (one per page)			
16. Specific lobbying issues				
Medicare prescription abroad	drug benefit legislation, inc	luding S. 1135;	internation	al issues affecting U.S. dri
17. House(s) of Congress a		ted 🔲	Check if N	None
U.S. House of Representa U.S. Senate U.S. Department of the In U.S. Department of Justin	nterior			
18. Name of each individua	·	this issue area		
Name (bolded na	mes are new lobbyists)		Covered C	Official Position (if applicable)
Stacy Carlson	Bill Paxon			
Smith W. Davis	Donald R. Pongrace			
Anthony Foti	Paul G. Scolese	:		
Gary A. Heimberg				
Jorge Lopez, Jr.				
Michael J. Parini				
P. Vincent LoVoi				
Thaddeus Burns				
19. Interest of each foreign en	tity in the specific issues listed	on line 16 above		Check if None
Signature	#a828ccc5-3f45-4ade-b0c5-b4e	∡ 85cd69911 - Page	 5 of 6	Date February 14, 20

Form LD-2 (Rev. 6/98) Pag